Exploring New Therapeutic Approaches for Refractory Glioblastoma
GC Cell announced on December 22 that its clinical study plan (IMPACT-GBM) for combination therapy using the standard treatment and Immuncell-LC Injection in newly diagnosed glioblastoma patients at Severance Hospital has received approval for suitability from the Ministry of Health and Welfare's Advanced Regenerative Medicine and Advanced Biopharmaceuticals Review Committee.
This study is an advanced regenerative medicine clinical trial led by Professor Noh Taehun of the Department of Neurosurgery at Severance Hospital, and will be conducted at a single institution over approximately 36 months. Glioblastoma is the most malignant type of brain tumor. Despite standard treatment, the prognosis remains poor, and ongoing clinical evaluations of various combination therapy strategies are being conducted for this disease.
The standard treatment for newly diagnosed glioblastoma includes radiotherapy and temozolomide chemotherapy following surgery. In this study, GC Cell’s autologous immune cell therapy, Immuncell-LC Injection, will be administered in combination with this standard regimen. The clinical efficacy will be evaluated in 20 patients, focusing on overall survival (OS) and disease progression indicators (PFS/DFS).
Professor Noh explained, “Glioblastoma is a representative intractable disease that has had no clear therapeutic alternatives beyond the standard treatment for over 20 years. This study is designed to assess the impact of combining anti-cancer immune cell therapy with standard treatment on survival indicators and the quality of life of patients.”
Immuncell-LC Injection is an autologous immune cell therapy in which immune cells are isolated and cultured from the patient’s own peripheral blood, activated, and then re-administered to the body. Based on its mechanism of inducing anti-cancer immune responses, it has accumulated clinical experience in certain indications such as liver cancer, and research continues to explore its potential application in the field of refractory solid tumors.
GC Cell CEO Won Sungyong stated, “This study is an attempt to clinically evaluate the combination strategy of immune cell therapy for patients with refractory glioblastoma, for whom treatment options are limited. We will work closely with the research team at Sinchon Severance Hospital to ensure the smooth progress of the study.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
